Cisplatin remains a valid option in muscle-invasive or metastatic urothelial carcinoma, and is even more efficient when nivolumab is added. The well-known side-effect profile and the limited number of treatment cycles represent great advantages over modern drug combinations such as enfortumab-vedotin plus pembrolizumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euf.2024.03.005 | DOI Listing |
Publication Analysis
Top Keywords
front-line platinum
4
platinum continues
4
continues role
4
role advanced
4
advanced bladder
4
bladder cancer
4
cancer cisplatin
4
cisplatin remains
4
remains valid
4
valid option
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!